Jakafi 20 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DR26FCRE6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,338
Award facts
- Contract value 100% obligated
- $12,338.41 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $12,338.41 to DMS Pharmaceutical Group Inc. for 60 tablets of JAKAFI 20 mg on October 27, 2025, with an ultimate completion date of October 28, 2025. This delivery order was issued under a firm fixed-price contract structure with no set-aside designation, indicating the award was made through unrestricted federal procurement competition. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain, specializing in distributing a comprehensive range of pharmaceutical products and medical consumables to the Department of Defense.
This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. As a regional prime vendor contractor under this framework, DMS Pharmaceutical Group is authorized to receive firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables to fulfill the specialized pharmaceutical requirements of the Department of Defense military medical system globally.
Quick answers
Who was awarded contract SPE2DR26FCRE6?
SPE2DR26FCRE6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DR26FCRE6 worth?
The government has obligated $12,338 on SPE2DR26FCRE6.
Is contract SPE2DR26FCRE6 an order under another contract?
Yes. SPE2DR26FCRE6 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRE6 competed?
The extent of competition for SPE2DR26FCRE6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award